DENTSPLY SIRONA (XRAY) Receives Media Impact Score of 0.18
News stories about DENTSPLY SIRONA (NASDAQ:XRAY) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DENTSPLY SIRONA earned a news impact score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.4747162884832 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- DENTSPLY SIRONA Inc. (XRAY) registers a price change of -0.62% while Infinity Pharmaceuticals, Inc. (INFI) finishes … – Stocks Gallery (stocksgallery.com)
- MannKind Corporation (MNKD) Hitting 0.20% Insider Ownership and DENTSPLY SIRONA Inc. (XRAY) Standing on … – Wallstreet Investorplace (wallstreetinvestorplace.com)
- DENTSPLY SIRONA Inc. (XRAY) Director Francis J. Lunger Sells 8,900 Shares (americanbankingnews.com)
- DENTSPLY SIRONA Inc. (XRAY) Insider Mark Thierer Buys 77,000 Shares (americanbankingnews.com)
- DENTSPLY SIRONA Inc. (XRAY) CFO Nicholas W. Alexos Purchases 50,000 Shares (americanbankingnews.com)
A number of research analysts have issued reports on the stock. UBS AG restated a “neutral” rating and set a $59.00 price target (down previously from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. BidaskClub lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, October 30th. Jefferies Group LLC decreased their price objective on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a report on Wednesday, August 23rd. Finally, Cleveland Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $67.00.
Shares of DENTSPLY SIRONA (NASDAQ:XRAY) traded up $1.21 on Thursday, reaching $66.60. 2,558,900 shares of the company’s stock traded hands, compared to its average volume of 1,653,762. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA has a 12 month low of $52.53 and a 12 month high of $67.95. The firm has a market cap of $15,018.96, a PE ratio of 26.05, a P/E/G ratio of 2.59 and a beta of 1.27.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. During the same period in the prior year, the company posted $0.66 EPS. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. sell-side analysts anticipate that DENTSPLY SIRONA will post 2.66 EPS for the current fiscal year.
In other DENTSPLY SIRONA news, CFO Nicholas W. Alexos acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Thierer acquired 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average price of $66.04 per share, for a total transaction of $5,085,080.00. The disclosure for this purchase can be found here. Corporate insiders own 1.99% of the company’s stock.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.